利妥昔单抗诱导缓解后必需型混合冷球蛋白血症与结缔组织病相关冷球蛋白血症的预后
回顾性研究纳入63例经利妥昔单抗为基础治疗达缓解的必需型或结缔组织病相关混合冷球蛋白血症血管炎患者,中位随访58个月。复发率1年23%、2年42%、5年71%;紫癜和既往复发与复发相关,维持治疗与早期复发风险降低相关。
要点
- 中位随访58个月,复发率1年23%、2年42%、5年71%。
- 紫癜(HR 2.2)和既往冷球蛋白血症血管炎复发(HR 1.9)与复发相关。
- 维持治疗与早期复发风险降低相关(HR 0.3),与晚期复发无显著关联。
核心结论
- 在以利妥昔单抗为诱导治疗的必需型和结缔组织病相关冷球蛋白血症血管炎患者中,复发频繁,与紫癜和既往复发相关,但维持治疗可减少复发。
研究设计与样本
- 回顾性研究,纳入63例经利妥昔单抗为基础治疗达缓解的必需型或结缔组织病相关混合冷球蛋白血症血管炎患者,中位随访58个月(IQR 33-88个月)。
主要发现
- 初始发作后复发率1年23%、2年42%、5年71%。
- 单因素分析中,与复发相关的因素为紫癜(HR 2.2;95%CI 1.1-4.4;P=0.02)和既往冷球蛋白血症血管炎复发(HR 1.9;95%CI 1.0-3.7;P=0.04)。
- 维持治疗与早期复发风险降低相关(HR 0.3;95%CI 0.1-0.9;P=0.03),但与晚期复发无显著关联(HR 2.0;95%CI 0.7-5.7;P=0.21)。
- 多因素分析中,无紫癜且无既往复发的患者较至少具有其中一项者复发风险更低(HR 3.6;95%CI 1.6-8.2;P=0.002)。
- 维持治疗方案与早期复发风险降低相关(HR 0.3;95%CI 0.1-0.9;P=0.03)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rituximab (RTX) and glucocorticoids are the first-line treatment for essential (EM) and connective tissue disease (CTD)-related mixed cryoglobulinemia vasculitis (CryoVas). Data on long-term outcomes of these CryoVas are lacking. We aimed to describe the prognosis of patients with EM and CTD-related CryoVas. METHODS: We conducted a retrospective study on patients with EM or CTD-related CryoVas in remission after RTX-based therapy. RESULTS: We included 63 patients with a median follow-up of 58 months (IQR, 33-88 months). Relapse rates were 23% at 1 year, 42% at 2 years and 71% at 5 years after the initial flare. In univariate analysis, factors associated with relapse were purpura [HR, 2.2; 95% confidence interval (CI), 1.1-4.4; P = 0.02] and a previous flare of CryoVas (HR, 1.9; 95% CI, 1.0-3.7; P = 0.04). Maintenance therapy was associated with a lower risk of early relapse (HR, 0.3; 95% CI, 0.1-0.9; P = 0.03), but not of late relapse (HR, 2.0; 95% CI, 0.7-5.7; P = 0.21). In multivariable analysis, patients without purpura or previous flare remained at lower risk of relapse than those with at least one of the two (HR, 3.6; 95%CI, 1.6-8.2; P = 0.002). Maintenance regimen was associated with a lower risk of early relapse (HR, 0.3; 95% CI, 0.1-0.9; P = 0.03). CONCLUSION: In patients with EM and CTD-related CryoVas who received RTX as induction therapy, relapses were frequent and associated with purpura and a previous flare but were reduced with maintenance therapy.
引用
- Poggi C, Hachulla E, Karras A, et al. Prognosis of essential mixed cryoglobulinemia and connective tissue disease-related cryoglobulinemia after rituximab-induced remission. Rheumatology (Oxford). 2025. PMID: 40493895. doi:10.1093/rheumatology/keaf324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。